Business Context and Reporting Period
Company: Evaxion A/S (Evaxion), a clinical-stage TechBio company specializing in AI-Immunology powered vaccines.
Filing Type: Form 6-K (Report of Foreign Private Issuer).
Reporting Period: Month of July 2025 (Filed July 17, 2025).
Principal Executive Offices: Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.
Key Financial Metrics and Material Changes
This filing reports a material debt settlement agreement rather than standard periodic financial results. Specific revenue, profit, cash flow, or margin data for the period is not provided in this text.
- Debt Reduction: Evaxion finalized a settlement with the European Investment Bank (EIB) to cancel EUR 3.5 million of its outstanding EUR 7.0 million loan.
- Equity Issuance: In exchange for the debt cancellation, the Company issued warrants to the EIB for 38,450,000 Ordinary Shares (represented by 769,000 American Depositary Shares).
- Warrant Terms:
- Exercise Price: DKK 0.25 per Ordinary Share.
- Exercisability: Immediately exercisable upon issuance.
- Expiration: 10 years from issuance.
- Liquidity Impact: The transaction reduces immediate debt obligations by 50% of the specific EIB loan facility without requiring immediate cash outflow, though it introduces potential future dilution.
Guidance, Outlook, and Management Commentary
The filing does not contain forward-looking financial guidance, revenue projections, or specific management commentary regarding operational outlook beyond the transaction details. The primary focus is the execution of the debt settlement and the associated legal agreements.
- Registration Rights: Evaxion agreed to file a registration statement with the SEC for the resale of the Ordinary Shares and Warrant Shares within 60 calendar days of the agreement. The Company must use commercially reasonable efforts to have the statement declared effective within 90 days (or 120 days in the event of a full SEC review).
- Corporate Governance: The Company amended its Articles of Association to authorize the granting of the warrants described above.
Risks and Contingencies
- Unregistered Securities: The Warrants and the shares issuable upon exercise have not been registered under the Securities Act of 1933. They may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption.
- Dilution Risk: The issuance of warrants for 38,450,000 shares represents a significant potential increase in the share count if exercised.
- Contractual Limitations: Representations and warranties in the agreements were made solely for the benefit of the contracting parties and may differ from standards applicable to investors.
Investor Verification Checklist
- Verify the total outstanding debt remaining with the EIB post-settlement (EUR 3.5 million).
- Confirm the exact number of authorized Ordinary Shares and the potential dilution impact of the 38,450,000 warrant shares.
- Monitor the filing status of the SEC registration statement for the resale of Warrant Shares (due within 60 days of July 11, 2025).
- Review the full text of the Debt Settlement Agreement (Exhibit 10.1) and Amendment Agreement (Exhibit 10.3) for any covenants or conditions not summarized here.
- Check subsequent filings for the effective date of the registration statement and any changes to the Company's capital structure.